Ahn Julie, Peng Shiwen, Hung Chien-Fu, Roden Richard B S, Best Simon R
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
Laryngoscope. 2018 Jan;128(1):E16-E20. doi: 10.1002/lary.26772. Epub 2017 Sep 4.
Although it has been shown that prophylactic vaccination can induce genital immunity, there is inadequate information on human papillomavirus (HPV) vaccine-induced oral immunity, which is of particular interest due to HPV-associated oropharyngeal malignancies and recurrent respiratory papillomatosis. Therefore, we assessed the efficacy of various HPV vaccines against oral HPV pseudovirus (PsV) infection in mice.
Preclinical scientific investigation.
C57BL/6 mice were vaccinated three times at 2-week intervals with either Gardasil (Merck, Kenilworth, NJ) (50 µL intramuscular injection) or a candidate pan-HPV L2 vaccine with alum adjuvant (25 µg subcutaneous injection). Additional mice were immunized with passive transfer of either Gardasil (Merck) human antisera or nonimmunized sera (100 µL intraperitoneal injection). All vaccinated and naïve control mice were then challenged with HPV16 E6E7 luciferase PsV in the oral mucosa. Visualization of HPV PsV infection was monitored through in vivo luciferase imaging.
Oral luciferase-expressing HPV16 PsV infection was not detected in Gardasil (Merck), L2 vaccine, and Gardasil (Merck) antisera-immunized mice, whereas robust luciferase expression was observed in all control mice. An in vitro neutralization assay from sera of Gardasil-vaccinated (Merck) mice confirmed that vaccine efficacy was due to neutralizing antibodies.
Oral HPV16 PsV infection in mice was completely prevented with all methods of prophylactic HPV immunization. These findings provide preliminary evidence that human vaccines induce protection against oral HPV infection, which has significant public health implications for HPV-associated oropharyngeal malignancies.
NA. Laryngoscope, 128:E16-E20, 2018.
尽管已表明预防性疫苗接种可诱导生殖器免疫，但关于人乳头瘤病毒（HPV）疫苗诱导的口腔免疫的信息不足，鉴于HPV相关的口咽恶性肿瘤和复发性呼吸道乳头状瘤病，这一点尤为重要。因此，我们评估了各种HPV疫苗对小鼠口腔HPV假病毒（PsV）感染的疗效。
临床前科学研究。
C57BL/6小鼠每隔2周接种3次，分别接种加德西（默克公司，新泽西州肯尼沃思）（50μL肌肉注射）或含明矾佐剂的候选泛HPV L2疫苗（25μg皮下注射）。另外的小鼠通过被动转移加德西（默克）人抗血清或未免疫血清（100μL腹腔注射）进行免疫。然后，所有接种疫苗的小鼠和未接种疫苗的对照小鼠在口腔黏膜中接受HPV16 E6E7荧光素酶PsV攻击。通过体内荧光素酶成像监测HPV PsV感染的可视化情况。
在接种加德西（默克）、L2疫苗和加德西（默克）抗血清的小鼠中未检测到口腔表达荧光素酶的HPV16 PsV感染，而在所有对照小鼠中均观察到强烈的荧光素酶表达。对接种加德西（默克）疫苗小鼠血清的体外中和试验证实，疫苗疗效归因于中和抗体。
所有预防性HPV免疫方法均可完全预防小鼠口腔HPV16 PsV感染。这些发现提供了初步证据，表明人用疫苗可诱导针对口腔HPV感染的保护作用，这对HPV相关的口咽恶性肿瘤具有重大的公共卫生意义。
无。《喉镜》，2018年，第128卷，E16 - E20页。
